ArticleACS chemical biology2016
Small Molecule Targeting of a MicroRNA Associated with Hepatocellular Carcinoma.
Article in ACS chemical biology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 46 citations in OpenAlex.
- Targeting RNA with small molecules, from RNA structures to precision medicines: IUPHAR review: 40.British journal of pharmacology · 2024Review
- Small molecules targeting microRNAs: new opportunities and challenges in precision cancer therapy.Trends in cancer · 2024Review
- Targeting MicroRNAs with Small Molecules.Non-coding RNA · 2024Review
- Trials and Tribulations of MicroRNA Therapeutics.International journal of molecular sciences · 2024Review
- Contemporary Progress and Opportunities in RNA-Targeted Drug Discovery.ACS medicinal chemistry letters · 2023Review
- DeepsmirUD: Prediction of Regulatory Effects on microRNA Expression Mediated by Small Molecules Using Deep Learning.International journal of molecular sciences · 2023Article
- Method for Identifying Sequence Motifs in Pre-miRNAs for Small-Molecule Binding.ACS chemical biology · 2022Article
- Improved Neomycin Sulfate Potency inMicroorganisms · 2022Article
- Non-coding RNAs in hepatocellular carcinoma: Insights into regulatory mechanisms, clinical significance, and therapeutic potential.Frontiers in immunology · 2022Review
- MicroRNA as an Important Target for Anticancer Drug Development.Frontiers in pharmacology · 2021Review
- Strategies to Modulate MicroRNA Functions for the Treatment of Cancer or Organ Injury.Pharmacological reviews · 2020Review
- Clinical Impact of Circulated miR-1291 in Plasma of Patients with Liver Cirrhosis (LC) and Hepatocellular Carcinoma (HCC): Implication on Glypican-3 Expression.Journal of gastrointestinal cancer · 2020Article
- miRNA inhibition by proximity-enabled Dicer inactivation.Methods (San Diego, Calif.) · 2019Article
- Development of miRNA-based therapeutic approaches for cancer patients.Cancer science · 2019Review
- Cyclic Peptidomimetics as Inhibitor for miR-155 Biogenesis.Molecular pharmaceutics · 2019Article
- MicroRNA-525 enhances chondrosarcoma malignancy by targeting F-spondin 1.Oncology letters · 2019Article
- Drugging the RNA World.Cold Spring Harbor perspectives in biology · 2018Review
- miR-665 promotes hepatocellular carcinoma cell migration, invasion, and proliferation by decreasing Hippo signaling through targeting PTPRB.Cell death & disease · 2018Article
- Review
- Therapeutic targeting of noncoding RNAs in hepatocellular carcinoma: Recent progress and future prospects.Oncology letters · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Development of precision therapeutics is of immense interest, particularly as applied to the treatment of cancer. By analyzing the preferred cellular RNA targets of small molecules, we discovered that 5"-azido neomycin B binds the Drosha processing site in the microRNA (miR)-525 precursor. MiR-525 confers invasive properties to hepatocellular carcinoma (HCC) cells. Although HCC is one of the most common cancers, treatment options are limited, making the disease often fatal. Herein, we find that addition of 5"-azido neomycin B and its FDA-approved precursor, neomycin B, to an HCC cell line selectively inhibits production of the mature miRNA, boosts a downstream protein, and inhibits invasion. Interestingly, neomycin B is a second-line agent for hepatic encephalopathy (HE) and bacterial infections due to cirrhosis. Our results provocatively suggest that neomycin B, or second-generation derivatives, may be dual functioning molecules to treat both HE and HCC. Collectively, these studies show that rational design approaches can be tailored to disease-associated RNAs to afford potential lead therapeutics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.